title: In vivo fluence rate effect in photodynamic therapy of early cancers with tetra(m-hydroxyphenyl)chlorin.
abstract: Several parameters affect clinical trials in photodynamic therapy and influence the therapeutic outcome. Beside drug dose, light dose, drug-light interval and other variables, the fluence rate is a parameter that can influence the therapeutic results. In this study we have evaluated the fluence rate effect with a second-generation photosensitizer, tetra(m-hydroxyphenyl)chlorin (mTHPC) using a 7,12-dimethylbenz(a)anthracene induced early squamous cell carcinoma of the Syrian hamster cheek pouch as a tumor model. Following injection of 0.5 mg/kg of mTHPC, irradiation tests were performed at two drug-light intervals, 4 and 8 days. Wavelength and light dose were adapted from those applied routinely in clinical trials. Irradiations at 652 nm were carried out with fluences ranging from 8 to 20 J/cm2 delivered at fluence rates of 15 and 150 mW/cm2. Similar tests were also performed at 514 nm with a fluence of 80 J/cm2 delivered at fluence rates ranging from 25 to 125 mW/cm2. At both wavelengths and drug-light intervals for a given fluence, the higher fluence rates resulted in less tissue damage in tumor and healthy mucosae. However, the lower fluence rates yielded slightly less therapeutic selectivity. This study confirms that the fluence rate is of major importance in clinical PDT.
authors.affiliation: Department of Otolaryngology Head and Neck Surgery, CHUV Hospital, Lausanne, Switzerland. Snezana.Andrejevic@chuv.hospvd.ch
authors.forename: S A
authors.initials: SA
authors.lastname: Blant
authors.forename: A
authors.initials: A
authors.lastname: Woodtli
authors.forename: G
authors.initials: G
authors.lastname: Wagnières
authors.forename: C
authors.initials: C
authors.lastname: Fontolliet
authors.forename: H
authors.initials: H
authors.lastname: van den Bergh
authors.forename: P
authors.initials: P
authors.lastname: Monnier
mesh_terms: D000818:Animals; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D006224:Cricetinae; D008647:Mesocricetus; D008652:Mesoporphyrins / Q000627:therapeutic use*; D009062:Mouth Neoplasms / Q000188:drug therapy*; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D010778:Photochemotherapy; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*
chemical_list: D008652:Mesoporphyrins; D011838:Radiation-Sensitizing Agents; C072269:temoporfin